Project Grant R21AI185539
Award Date
8/20/24
Completion Date
7/31/26
Dollars Obligated
$457K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $426,648 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Dartmouth-Hitchcock Clinic. The grant, titled "ADVANCING ANTIMICROBIAL PHOTODYNAMIC THERAPY TO PREVENT INFECTION IN OSSEOINTEGRATED PROSTHESIS PATIENTS," will fund research to develop antimicrobial photodynamic therapy for preventing infections in patients with osseointegrated prosthetic implants. As part of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $206,283 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant, effective August 16, 2024 through July 31, 2029, will support research to investigate the effects of targeting immune activation and intestinal barrier on comorbidities in people living with HIV. The research aims to advance...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to establish a CRISPR-based airway organoid platform for screening mechanisms involved in airway epithelial cell and intraepithelial airway macrophage interactions. The goal is to identify novel mediators of airway immune cell homeostasis,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $800,005 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the structural basis and functional impacts of genetic variants in G-protein coupled receptors (GPCRs) associated with autoimmune diseases. The project aims to: 1) define the structural basis for impaired...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $473,937 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a novel point-of-care liquid biopsy for early detection of sepsis-associated organ damage. The project aims to optimize a microfluidic enrichment and digital PCR assay to detect tissue-derived circulating rare cells...
This $197,160 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to define the mechanisms by which extracellular matrix (ECM) stiffness regulates the NLRP3 inflammasome in macrophages. The project aims to: 1) Define how ECM stiffness regulates the transcription factor NRF2 activity in vitro; and 2) Determine the role of NRF2 regulation of the NLRP3 inflammasome in fibrotic interstitial lung...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $710,018 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Dartmouth-Hitchcock Clinic to evaluate the use of indocyanine green (ICG) fluorescence imaging for rapid diagnosis of necrotizing soft-tissue infections (NSTIs). The project aims to conduct a prospective, observational, multicenter clinical study to assess the ability of dynamic contrast-enhanced fluorescence imaging (DCE-FI) with...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research on the role of ZNF proteins in establishing and maintaining HIV latency. The two-year project aims to evaluate how ZNF proteins impact the epigenetic landscape in primary CD4+ T cells and explore mechanisms of HIV latency...
This Cooperative Agreement award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Grant Program (CFDA 93.855), supports research to enhance understanding of the phenotypes, endotypes, and mechanisms of immediate-onset allergic reactions to antibiotics. The total funding amount is $427,671, with the project period running from July 3, 2025 to June 30, 2027. The awardee, The General Hospital Corporation doing business...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to investigate the role of a novel monocyte transcriptional state, termed "monocyte substate 1" (MS1), in the immunopathogenesis and patient heterogeneity of sepsis. The 5-year project will apply single-cell RNA...